Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
复制标题
DOI：
10.1038/sj.bjc.6605112
复制
发表时间：
2009-07-07
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
p53，EGFR和HER-2/NEU是上皮卵巢癌中最常研究的分子生物学参数，但它们的预后影响仍然是明确的。
使用渠道识别了p53，EGFR和HER-2/NEU状态与HER-2/NEU状态之间的关联的研究。回归分析。
总共包括62份研究，p53，EGFR的15个研究，HER-2/NEU，EGFR，EGFR和HER-2/NEU状态对整体生存具有适度p53; HR 1.65，95％CI 1.25-2.19，HR 1.67，95％CI 1.34–2.08用于HER-2/NEU）研究结果。
尽管P53，EGFR和HER-2/NEU状态适度影响生存，但这些标记本身不太可能作为临床实践中的预后标记有用。预后因素研究的结果。
P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance. Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian–Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis. A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33–1.61 for p53; HR 1.65, 95% CI 1.25–2.19 for EGFR and HR 1.67, 95% CI 1.34–2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present. Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies.
登录
查看更多内容
在多中心研究中，影响卵巢癌p53表达的因素是临床结果的生物标志物。
影响因子：
8.8
作者：
de Graeff, P;Hall, J;Crijns, A P G;de Bock, G H;Paul, J;Oien, K A;ten Hoor, K A;de Jong, S;Hollema, H;Bartlett, J M S;Brown, R;van der Zee, A G J
通讯作者：
van der Zee, A G J
影响因子：
6.2
作者：
Castellvi, Josep;Garcia, Angel;Ramon y Cajal, Santiago
通讯作者：
Ramon y Cajal, Santiago
DOI：
10.1097/01.pgp.0000235064.93182.ec
发表时间：
2007-04-01
影响因子：
2.4
作者：
Brustmann, Hermann
通讯作者：
Brustmann, Hermann
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
8.8
作者：
de Graeff, P.;Crijns, A. P. G.;ten Hoor, K. A.;Klip, H. G.;Hollema, H.;Oien, K.;Bartlett, J. M.;Wisman, G. B. A.;de Bock, G. H.;de Vries, E. G. E.;de Jong, S.;van der Zee, A. G. J.
通讯作者：
van der Zee, A. G. J.